• Topics

  • Formats

As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution.

  • How has the emphasis on patient experience changed the drug development landscape?
  • What changes have the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) implemented to emphasise patient input in drug development?
  • How have scientific and technological innovations contributed to the development of more personalised and effective therapies in oncology?
  • What are the benefits of involving patients earlier in the drug development phase, especially in oncology?
  • What challenges remain in fully integrating patient perspectives into drug development and commercialisation?

Reading this content is completely free

Enjoy Unlimited Access and Unlock
Additional Features with a Free Account

Join Now

You are attempting to log out of MyMA

Do you really want to log out?